XE heads into the week having shed nearly a third of its value in a month, with a freshly initiated bearish analyst rating, a well-known investor on the 13G register, and an earnings history that punishes patience — making this one of the more charged setups in the small-cap nuclear space right now.
The most consequential development this week came from the Street. Piper Sandler initiated coverage on September 9 with an Underweight rating and a $9 price target — a level implying roughly 40% further downside from the current $14.93 close. That sits in sharp contrast to Guggenheim, which reiterated its Buy on the same day with a $57 target, and to Cantor Fitzgerald and JP Morgan, which both carry Overweight ratings with targets in the high $30s. The resulting consensus rating is a formal "Sell," yet the mean price target of $34.38 reflects how wide the bull-bear gap remains. The Piper initiation is worth taking seriously given its recency, but the $57 Guggenheim target — anchored to an EV/EBITDA thesis based on a 2032 commercialization outlook — illustrates exactly what the debate is: this is a stock where your investment horizon matters more than almost any near-term data point.
The bull case rests on structural demand: X-Energy's partnerships with Amazon, Dow, and Centrica, an 11.5GW contract pipeline, and proprietary TRISO-X fuel technology that is difficult to replicate. Bears counter with a simpler argument — the technology is unproven at scale, the commercialization path depends heavily on government support, and the company is burning cash against an uncertain regulatory timeline. HALEU fuel supply constraints add an operational wrinkle that doesn't appear in any of the bullish models. The EV/EBITDA multiple is currently -19.4x, a figure that meaningfully improved over the past month as the share price fell, but it remains untethered from positive earnings in any near-term scenario. Price-to-book at 3.6x has compressed 13% over 30 days, and the ORTEX stock score has fallen from 41 to 28 over a similar window — near its lowest reading of the period.
The ownership register adds an unusual layer to the picture. Amazon holds 22.9% of shares as a strategic partner — a genuine anchor. Founder Kamal Ghaffarian retains 25%, filed as a passive 13G holder. Ares Partners has disclosed a 12.3% passive stake. Kenneth Griffin holds 6.8% via a 13G, and Jane Street filed a fresh 13G on September 4 disclosing 5.2%. All of these are passive Schedule 13G filings — no activist 13D is on the register, so there is no activist catalyst in play. The caveat worth carrying: 13D/G stakes are event-driven disclosures around the 5% threshold, and any holder who drops below that level may exit without filing again. What the register does confirm is that the free float is tighter than the headline share count suggests, with insiders, the founder, and strategic investors collectively accounting for a significant portion of shares outstanding.
Options positioning, by contrast, is not flashing alarm. The put/call ratio has actually declined from mid-August levels near 0.67 to around 0.51, slightly below its 20-day average of 0.55 — a z-score of roughly -0.42. That means options traders are not positioning for a sharp drop; hedging activity has eased even as the stock has sold off. The divergence between the price action (-27% in a month) and the PCR trajectory is notable. Post-earnings reactions offer limited comfort — the most recent print on September 3 produced a -2.2% one-day move and a -12.5% five-day move, while the August 13 event saw an initial +3.1% gain that then reversed to -10.1% over the following week.
The next earnings event is flagged for November 13 — the clearest near-term marker on the calendar for whether any of the commercialization milestones are advancing, and whether HALEU supply constraints are easing enough to support the 2027-onward ramp that underpins the bull case price targets.
See the live data behind this article on ORTEX.
Open XE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
